We are science visionaries who want to end cancer’s reign.

Approximately 10 million lives are lost to cancer annually. This makes it the second leading cause of death globally. Therapeutic process is happening – but is excruciatingly slow. The potential for developing novel, more powerful biotherapeutics is exhausted with conventional methods. This is about to change with our unique AI-driven drug discovery and development platform. We at BioCopy are overcoming the decisive hurdles of truly effective cancer treatment:

• An extremely difficult, tedious, and costly discovery and development process
• Problems in the transition from early-stage discovery and development towards industrial-scale production with a high rate of failure
• A relevant risk that biotherapeutics not only kill cancer cells but also damage healthy cells, which can lead to life-threatening side effects.

We are cancer’s nemesis

It seems that cancer is always ahead of medicine, that it is too fast and outsmarts human biology. This is not true. The body‘s own immune system is highly efficient in fighting cancer cells. However, cancer cells are extremely adept at evading our body’s immune surveillance. This is why special drugs are needed, which enable our immune cells to chase tumor cells, so that they can fully unleash their cancer-fighting power. The drugs achieve this by recognizing cancer cells and directly linking them to an immune cell. They are highly complex biotherapeutics.

As a consequence, the drug discovery and development of such biotherapeutics is tedious, costly and error-prone. In addition, the way current biotherapeutics recognize cancer cells is far from perfect. This goes hand in hand with a high risk, that current biotherapeutics might damage healthy cells, leading to life-threatening side effects.

This is where BioCopy comes into play. We are the world’s first research-based biotechnology company with an artificial intelligence (AI)-driven, end-to-end automated, proprietary platform. We discover and develop highly powerful yet safe drug candidates for future biotherapeutics at an unprecedented speed, quality, and quantity. They identify cancer cells more accurately than ever before, making them safer and more efficient than conventionally-developed drugs. This unleashes the immune system’s power on a scale that has never been seen before.

We have three programs underway in solid tumors (bladder cancer, ovarian cancer, lung cancer), starting in 2024/2025 and two in blood cancer (acute myeloid lymphoma), beginning in 2025/2026. Our plan for the next three to four years: Provide drug candidates for clinical evaluation from all five of these programs.

Powerful drug candidates beyond cancer

One of BioCopy’s key advantages is that our platform is not limited to cancer biotherapeutics. Its broad applicability comes with the huge potential of providing powerful drug candidates for other severe diseases as well. Our longer-term goal is to discover and develop next-generation biotherapeutics for immunological and neurological disorders.

BioCopy was founded in 2019. Our technology was quickly recognized as leading-edge in early drug discovery, drug candidate safety and efficacy assessments. When we joined forces with Perspix BioTech and their automated laboratory in early 2024, we took drug discovery and development to a completely new level.

Not only did we solve current obstacles in optimization and development of complex biotherapeutic candidates, we now have an AI-driven, end-to-end automated platform, that enables development of highly efficient, safe, and multispecific biotherapeutics – similar to a Swiss army knife – at an unprecedented speed. The platform allows design and development of an unlimited number of biotherapeutics mimicking industrial production processes. This makes BioCopy a key partner for pharmaceutical industries, when it comes to bringing next-generation biotherapeutics to market.

The acquisition of Perspix Biotech marks a milestone for BioCopy on our mission to end cancer’s reign. It is the latest in a series of important acquisitions we have made in recent years. With these we have optimally aligned our business towards developing highly effecive and safe cancer drug candidates.

Wirtschaftswoche magazine ranks Matthias Wiedenfels among Germany's biotech pioneers of the coming decade.

Basel, Dec 6, 2024. BioCopy AG is proud to announce that the renowned WirtschaftsWoche, a medium of the Handelsblatt Media Group, has selected Matthias Wiedenfels as a winner of “Germany's 30 by 2030”. With this award, the editorial team honors 30 outstanding personalities who, through their innovative strength and commitment, are making a significant contribution to shaping Germany's future by 2030. >>read more

>> read our Press Release in German

>> to the WirtschaftWoche article

BioCopy chooses Genedata for AI-powered Multi-specific Antibody Discovery

Basel, July 17, 2024. By implementing the leading enterprise software solution for bio-pharmaceutical R&D, BioCopy takes the necessary step towards its AI-powered high-quality engineering of next-generation cancer therapeutics. >> read more

Game Changer in Fighting Cancer: BioCopy expands corporate portfolio with acquisition of Perspix Biotech GmbH

Basel, April 9, 2024. BioCopy AG, a research-based biotechnology company headquartered in Basel, Switzer-land, today announced the acquisition of Perspix Biotech GmbH. Founded in 2021 and based in Frankfurt am Main, Germany, Perspix Biotech with its end-to-end automated platform roPROTix combines artificial intelligence and robotics for the discovery and development of next-generation multispecific biotherapeutics. As part of BioCopy AG, Perspix Biotech GmbH will be renamed as BioCopy Analytix GmbH and provide analyti-cal and other services to the company group. >> read more

Press Release 2022-12-05

BioCopy patent for complex array fabrication process granted much earlier than usual: setting new standards in the state of the art for kinetic binding measurement. >> read more

Press Release 2022-03-29

BioCopy AG presents ValidaTe, a novel ultra-fast screening technology to significantly speed up drug discovery. >> read more

• WirtschaftsWoche. December 6 2024. "Wo Deutschland bei Biotech Spitze ist. Organe aus dem 3D-Drucker, eine Technologie, die Krebsherde aufspürt und ein neues Verfahren gegen Herzleiden: Deutschland sprudelt vor Biotech-Ideen." >> read more

• Wirtschaft mit Weisbach. Episode 23. "Kann KI die Krebsforschung revolutionieren?" 14. Juni 2024 >>listen in

• Market access and health policy magazine: "Den heiligen Gral der Wirkstoffentwicklung bei Biotherapeutika entdeckt". Issue 04/2024. >> read more

• Pharma Focus Europe: "Accelerating the Drug Development Process". Issue 04/2024. >> read more

• Euro Health Leaders: "Matthias Wiedenfels - Visionary Leader in Next-Gen Drug Discovery". Issue 03/2024. >> read more

Awards

• Forbes Magazine listed BioCopy in 2021 as one of the 30 Spin-offs to watch (https://www.forbes.at/artikel/spin-offs-to-watch-2021.html)
• The Royal Society of Chemistry (RSC) Emerging Technologies of London lists the BioCopy concepts “AptaSWIFT” and “immune2day” in the TOP 10 of Health technologies in 2015 (during early spin-off phase)

Selected Publications

• Kraemer S et al., An ultra-high-throughput screen for the evaluation of peptide HLA-Binder interactions; Sci Rep. 2023; 13 (1): 5290; doi: 10.1038/s41598-023-32384-z.
• Ziegengeist T et al., High-Throughput and Format-agnostic Mispairing Assay for Multispecific Antibodies using Intact Mass Spectrometry. Anal Chem 2023; 95 (27); doi: 10.1021/acs.analchem.3c00742.
• An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics. MAbs. 2021; 13 (1):1955433; doi: 10.1080/19420862.2021.1955433.